DOCSLIB.ORG

Partnering for a Pandemic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Partnering for a Pandemic FEATURE Partnering for a pandemic History has shown that collaborative efforts can have a crucial role in combating Credit: S.Fenwick/ viral outbreaks such as the current coronavirus pandemic. Springer Nature Limited Raveena Bhambra As coronavirus continues to spread, organizations around the Inovio Pharmaceuticals had started up vaccine development pro- world are working together to tackle the urgent needs for diagnos- grams, with these front-runners taking advantage of the rapidity tic, treatment and prevention strategies. In this article, we explore with which the underlying mRNA- or DNA-based platforms can the wave of partnerships that have been established to accelerate be used to identify vaccine candidates. They were soon joined by the development of vaccines for the prevention of COVID-19. others, ranging from universities and large pharma companies that are most active in the vaccine field in general, including Pandemic preparedness Sanofi, GlaxoSmithKline (GSK), Pfizer and J&J. As of early May, In the past decade, the world has already faced two viral out- almost 100 vaccines were being developed (Nature 580, 576–577; breaks that have caught regions off guard. In 2014, the Ebola 2020), harnessing various platforms to design candidates, involv- virus surfaced in Western Africa. With an urgent need for infec- ing peptides, nucleic acids, virus-like particles, viral vectors, tion control, but no approved therapies or vaccines and only a recombinant protein, live attenuated virus and inactivated viruses handful of vaccine candidates available, partnering was a must. (Nat. Rev. Drug Discov. 19, 305–306; 2020). A number of companies joined forces, including Johnson and Partnering has been crucial in tackling the challenges of highly Johnson (J&J), who partnered with Bavarian Nordic to develop novel vaccine discovery and development at such pace (Fig. 1). For a viral vector-based vaccine, and Merck & Co., who partnered example, Moderna—whose mRNA-based vaccine mRNA-1273 with Newlink Genetics to rapidly develop and test its recombi- targeting the viral spike protein was the first to enter clinical tri- nant vaccine rVSV-ZEBOV (BioPharma Dealmakers, B15–17, als in mid-March—was working on the candidate with the US June 2016). This candidate would eventually go all the way to be National Institute of Allergy and Infectious Diseases (NIAID) just approved by the US Food and Drug Administration in 2019 as the 2 days after the virus sequence was released, and shortly after- first vaccine for Ebola. Now named Ervebo, it was already being wards received funding from CEPI to support its development. applied from 2018 in another Ebola outbreak in the Democratic Given the likely need for vast amounts of any successful vac- Republic of the Congo. cines, adjuvants that enhance vaccine immunogenicity and make Shortly after the Ebola epidemic, Zika virus began to spread lower doses viable will be important. So, with only a small number through South America in 2015. However, with relatively little of licensed adjuvants available, there has been a flurry of part- known about the virus, researchers didn’t have the head start they nerships around them. Two vaccine big hitters, Sanofi and GSK, had with Ebola—similar to the current situation with COVID-19. made headlines when they announced they would join forces. Again, organizations and pharma companies came together to Sanofi will contribute its spike protein antigen, which is based develop vaccines, and although the epidemic subsided by the end on recombinant DNA technology, while GSK will contribute of 2016, several vaccines have progressed into clinical trials, put- its adjuvant technology in the partnership. GSK and CEPI have ting potential responses to future outbreaks on stronger ground. established a collaboration to make GSK’s adjuvant platform avail- The responses to these two outbreaks highlighted the key need able to vaccine developers being funded by CEPI, and companies for coordination strategies and funding for efforts to combat including Dynavax and Seqirus are also committed to making future pandemics. Adding to established organizations such as licensed adjuvants available to vaccine developers. the European Innovative Medicines Initiative and the US Office Finally, the need for large-scale manufacturing of successful vac- of Biomedical Advanced Research and Development Authority cines has generated deals. For example, in March, Pfizer expanded (BARDA), the Coalition for Epidemic Preparedness and an existing 2018 influenza vaccine partnership with BioNTech Innovations (CEPI) was set up in 2017 specifically to coordinate to co-develop and manufacture BioNTech’s mRNA vaccines for the work of public, private, philanthropic and civil organizations COVID-19, which are notable in that the clinical trial program for vaccine development to stop epidemics. And in the current is testing four vaccine candidates, with different combinations crisis, CEPI has a key role in mobilizing funding and coordinating of mRNA format and target antigen. And in April, AstraZeneca efforts for many organizations developing a COVID-19 vaccine. announced a partnership with the University of Oxford on the development, manufacture and distribution of their adenovirus- Partnering at pace based vaccine targeting the spike protein. Moderna followed suit Within days of the genome sequence of SARS-CoV-2, the coro- by partnering with Lonza to enable the manufacturing of up to 1 navirus that causes COVID-19, being shared on 11 January 2020, billion doses per year of its vaccine if it is successful—underlining biotech companies including Moderna, BioNTech, CureVac and just how big a challenge counteracting COVID-19 has become. B18 | June 2020 | biopharmadealmakers.nature.com FEATURE 23 January Moderna receives funding 31 January from CEPI to support CureVac collaborates with development of its vaccine, CEPI to take potential in partnership with the VRC vaccine candidates into of the NIAID, part of the NIH clinical testing 3 February Collaborating with CEPI, 11 February GSK makes its vaccine Janssen Pharmaceutical adjuvant platform Companies (part of J&J) technology available to partners with BARDA to 17 March CEPI-funded entities to accelerate its vaccine Pfizer to jointly develop a vaccine. program develop BioNTech’s 4 March mRNA-based vaccine candidate BNT162 7 February 24 February Using Arcturus LineaRx, Applied DNA Clover Biopharmaceuticals Therapeutics’ STARR Sciences subsidiary, will use GSK’s adjuvant technology, Duke–NUS 18 March collaborates with Takis technology to develop its Medical School partners Emergent BioSolutions Biotech to develop linear preclinical vaccine with Arcturus to develop announces DNA vaccine candidate candidate (COVID-19 a vaccine development and S-Trimer) manufacturing deal 13 March with Vaxart for their Janssen Pharmaceutical oral vaccine candidate Companies collaborates with the BIDMC to advance the development 27 March of a vaccine candidate Expanding 2018 mRNA vaccine deal, 3 April Sanofi Pasteur and Innovax Biotech partners 23 April 16 March Translate Bio develop with GSK to use their Janssen Pharmaceutical BioNTech partners with vaccine candidate adjuvant in preclinical Companies partners Fosun Pharma to conduct together testing of candidate with Emergent trials of its vaccine COVID-19 XWG-03 with BioSolutions for BNT162 in China Xiamen University manufacturing support 31 March of its lead vaccine VBI Vaccines candidate collaborates with the 14 April NRC to develop a Combining their pan-coronavirus innovative technologies, 30 April vaccine candidate Sanofi and GSK team up AstraZeneca teams up to develop an with the Jenner adjuvanted vaccine Institute and Oxford Vaccine Group at the 1 May University of Oxford to Moderna signs 10-year large-scale 16 April develop, manufacture manufacturing deal for its vaccine Dynavax provides its and distribute their candidate mRNA-1273 with Lonza adjuvant, CpG 1018, to vaccine candidate develop Sinovac’s ChAdOx1 11 May vaccine candidate. CEPI expands March 2020 deal with Novavax to accelerate development and manufacture of their NVX-CoV2373 candidate Fig. 1 | The world’s most wanted vaccine. Selected biopharma partnering deals relating to the development, manufacture and distribution of a potential vaccine against COVID-19 in 2020. BARDA, Biomedical Advanced Research and Development Authority; BIDMC, Beth Israel Deaconess Medical Center; CEPI, Coalition for Epidemic Preparedness Innovations; J&J, Johnson & Johnson; NIAID, National Institute of Allergy and Infectious Diseases; NRC, National Research Council of Canada; VRC, Vaccine Research Center. Data taken up to 18th May 2020. biopharmadealmakers.nature.com | June 2020 | B19 .
Load more

Recommended publications
  • What You Need to Know About Rabies
    WHAT YOU NEED TO KNOW ABOUT RABIES ASSOCIATION OF IMMUNIZATION MANAGERS FEBRUARY 2021 Bavarian Nordic is a fully integrated, leading biotechnology company focused on the research, development, innovation, manufacturing and commercialization of vaccines for the prevention and treatment of life-threatening diseases 1 VIRAL DISEASE ALMOST ALWAYS FATAL IF UNTREATED Paralytic rabies Ascending spread of flaccid Classical (furious) rabies Onset of coma DEATH muscle weakness, bilateral Hyper-excitability, periods weakness of facial muscles, of confusion, hallucinations, sphincter involvement agitation and hydrophobia Coma (0–14 days) Acute neurological phase (2–7 days) Nonspecific symptoms Fever, malaise, chills, fatigue, First neurological signs insomnia, anorexia, headache, (>10 days) anxiety, irritability Prodromal phase (2–10 days) Exposure Bite or scratch from, or Incubation of virus mucosal contact with, (20–90 days) a rabid animal 1. Jackson et al. In Rabies (2nd edition). Chapter 7. 2007: 309–340; 2. WHO. Wkly Epidemiol Rec 2018; 93: 201–20; 3. Hemachudha et al. Lancet Neurol 2002;1:101–9; 4. WHO. Rabies: Fact Sheet. https://www.who.int/en/news-room/fact-sheets/Detail/rabies [accesseD July 2020]. PREVALENCE IN THE USA Rabies transmission in dogs has been virtually eliminated in the USA, in part due to widespread canine vaccination programs5 • As a result, wildlife has accounted for >90% of rabid animals reported in the USA since 19805-7 • Primary vectors in this region are skunks, foxes, raccoons, bats and mongooses (in Puerto Rico)5-7 • In the US, the primary rabies vector is the bat due to encounters with bats that may be less recognized e.g.
    [Show full text]
  • Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership
    VALNEVA SE Campus Bio-Ouest | 6, Rue Alain Bombard 44800 Saint-Herblain, France Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership Saint-Herblain, France, June 18, 2020 – Valneva SE, (“Valneva”), a specialty vaccine company, and Bavarian Nordic A/S (OMX: BAVA) today announced that they have signed a binding term sheet to establish a partnership for the marketing and distribution of their commercial products. The partnership will provide both companies with additional critical mass, significant commercial synergies and a market leadership position in the specialty vaccine industry. Under the agreed terms, Valneva will commercialize Bavarian Nordic’s marketed vaccines leveraging its commercial infrastructure in Canada, UK, France and Austria. Valneva will also take responsibility for Belgium and the Netherlands where it will set up new commercial operations. Bavarian Nordic will commercialize Valneva’s marketed products in Germany and Switzerland. The partnership includes vaccines that protect against rabies, Japanese Encephalitis, tick-borne encephalitis and cholera. The agreement follows Bavarian Nordic’s recent acquisition of two commercial vaccines from GlaxoSmithKline. The transition from current arrangements will commence later this year and through 2021 in line with existing distribution agreements. Valneva expects limited additional revenues in 2020 with more material impact from 2021 onwards. Thomas Lingelbach, CEO of Valneva, commented, “We are excited to join forces with Bavarian Nordic to continue to build our commercial business and to enhance our product offering to our customers. This partnership provides excellent synergy for both companies as well as greater breadth in our commercial portfolios.” Paul Chaplin, President & CEO of Bavarian Nordic, added, “We are pleased to collaborate with Valneva in the ongoing commercialization of our business.
    [Show full text]
  • Written Statement for Dr. Anthony Fauci, Director, NIAID
    DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH The Role of the National Institute of Allergy and Infectious Diseases Research in Addressing Ebola Virus Disease Testimony before the House Foreign Affairs Committee Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations Anthony S. Fauci, M.D. Director National Institute of Allergy and Infectious Diseases September 17, 2014 Mr. Chairman and Members of the Committee: Thank you for the opportunity to discuss the National Institutes of Health (NIH) response to the global health emergency of Ebola virus disease. I direct the National Institute of Allergy and Infectious Diseases (NIAID), the lead institute of the NIH for conducting and supporting research on infectious diseases, including viral hemorrhagic fevers such as those caused by Ebola virus infection. For over six decades, NIAID has made important contributions to advancing the understanding of infectious, immunologic, and allergic diseases, from basic research on mechanisms of disease to applied research to develop diagnostics, therapeutics, and vaccines. NIAID has a dual mandate that balances research addressing current biomedical challenges with the capacity to respond quickly to newly emerging and re-emerging infectious diseases, including bioterror threats. Critical to these efforts are NIAID’s partnerships with academia and pharmaceutical companies, and collaborations with other federal entities, particularly the Centers for Disease Control and Prevention, the Food and Drug Administration (FDA), the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense. OVERVIEW OF EBOLA VIRUS DISEASE Viral hemorrhagic fevers are severe illnesses that can be fatal and are caused by a diverse group of viruses including Marburg virus, Lassa virus, and Ebola virus.
    [Show full text]
  • Bavarian Nordic Annual Report 2018 Management Commentary | Financial Statements
    Unlocking the power of the ANNUAL immune system REPORT 2018 199425 2019 YEARS OF GREAT ACHIEVEMENTS IN THE VACCINE SPACE STIMULATING THE IMMUNE SYSTEM GIVING HOPE TO MILLIONS Management commentary | Financial statements CONTENTS MANAGEMENT FINANCIAL COMMENTARY STATEMENTS INTRODUCTION BUSINESS AND PIPELINE CONSOLIDATED FINANCIAL STATEMENTS Letter from the CEO & chairman .................... 4 Product pipeline.................................. 20 Consolidated income statements .................. 68 At a glance ....................................... 6 Infectious disease ................................ 22 Consolidated statements of comprehensive 25 years of great achievements .................... 8 Our partnership with Janssen ...................... 28 income .......................................... 68 Key developments................................ 10 Cancer immunotherapy ........................... 36 Consolidated statements of cash flow.............. 69 A word from the new CFO......................... 12 Chordoma........................................ 38 Consolidated statements of financial position Strategy track ................................... .16 – assets ......................................... 70 Financial results for 2018 ......................... .18 CORPORATE INFORMATION Consolidated statements of financial position The Bavarian Nordic share ........................ .46 – equity/liabilities ............................... 71 Corporate social responsibility .................... .48 Consolidated statements of changes in
    [Show full text]
  • CP-162837 Johnson & Johnson Announces European Commission
    News Release Media Contacts: Seema Kumar +1 908-405-1144 [email protected] Sarah Smith +44 7920 082012 [email protected] Investor Relations: Jennifer McIntyre +1 732-524-3922 Chris DelOrefice +1 732-524-2955 Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine This marks the first major regulatory approval of a vaccine developed by Janssen The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19 NEW BRUNSWICK, N.J., 1 July 2020 – Johnson & Johnson today announced that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies’ Ebola vaccine regimen for the prevention of Ebola Virus Disease. Enabled by this approval, Janssen is now collaborating with the World Health Organization (WHO) on vaccine pre-qualification, which should help accelerate registration of its preventive Ebola vaccine regimen in African countries and facilitate broader access to those most in need. Two Marketing Authorisation Applications (MAAs) were submitted to the European Medicines Agency (EMA) for the vaccines composing the two-dose regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo). Marketing Authorisation under exceptional circumstances has been granted following Accelerated Assessment of the MAAs and a positive opinion by the EMA’s Committee for Medicinal Products for Human Use (CHMP). Janssen’s Ebola vaccine regimen is indicated for active immunization for the prevention of Ebola Virus Disease caused by the Zaire ebolavirus species in individuals aged one year and above.
    [Show full text]
  • Johnson & Johnson Joins World Health Organization in Efforts To
    Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa May 13, 2021 Up to 200,000 Johnson & Johnson Ebola vaccine regimens will be made available as part of a WHO early access clinical program now underway in Sierra Leone Company's Ebola vaccine regimen also receives Prequalification from the WHO The Johnson & Johnson vaccine regimen is designed to be used proactively to induce immunity against Ebola in adults and children NEW BRUNSWICK, N.J., May 13, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the World Health Organization (WHO) and the government of Sierra Leone have begun administering the Company's Ebola vaccine regimen as part of a WHO early access clinical program aimed at preventing further spread of Ebola in West Africa. The vaccine regimen, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) in collaboration with Bavarian Nordic A/S, is being donated to the WHO by Janssen for the purposes of the early access clinical program. Johnson & Johnson also announced that its Ebola vaccine regimen has received Prequalification from the WHO, which will help accelerate its registration in countries where Ebola is a persistent public health threat and facilitate broader access to people at risk of exposure to this virus. Health authorities in Guinea officially declared a new Ebola outbreak in February 2021 after the West African country experienced its first cases of disease since the end of the 2014-2016 Ebola outbreak – which was the worst on record. Preliminary data obtained through genetic sequencing suggest that the new outbreak was caused by the same virus strain also responsible for the 2014-2016 outbreak and was likely reintroduced by a survivor.
    [Show full text]
  • Ebola Outbreaks in the Democratic Republic of Congo: Emergencies Or Enduring Threat?
    Ebola Outbreaks in the Democratic Republic of Congo: Emergencies or Enduring Threat? Updated September 10, 2020 Congressional Research Service https://crsreports.congress.gov R45933 SUMMARY R45933 Ebola Outbreaks in the Democratic Republic of September 10, 2020 Congo: Emergencies or Enduring Threat? Tiaji Salaam-Blyther On June 25, 2020, the World Health Organization (WHO) announced the end to an Specialist in Global Health Ebola outbreak that began nearly two years earlier in eastern Democratic Republic of th Congo (DRC). The outbreak—DRC’s 10 on record—was concentrated in a conflict Alexis Arieff zone, complicating containment efforts, and became the world’s second-largest Ebola Specialist in African Affairs outbreak ever. Attacks on health workers repeatedly impeded containment efforts, as did political tensions, local community suspicion of government officials and international actors, and local frustrations at perceived profiteering by responders. Eventual success in containing the outbreak was attributable, in part, to the deployment of new vaccines first pioneered during the West Africa outbreak, advances in experimental therapeutics, and changes in the coordination of response efforts on the ground. Relief over ending the 2018-2020 eastern DRC Ebola outbreak was muted, however, by the detection of a new outbreak, DRC’s 11th to date, in the western part of the country in the same month—and by the global Coronavirus Disease 2019 (COVID-19) pandemic, which has posed new health challenges in DRC and severely affected the country’s economy. The DRC government and international partners also face other health challenges, including intermittent outbreaks of measles, cholera, and malaria, and relatively high preventable death rates (particularly in the areas of maternal and child health) resulting from inadequate access to clean water, sanitation, and hygiene (WASH) and primary health care.
    [Show full text]
  • Bavarian Nordic
    THE FUTURE OF VACCINES DECEMBER 2016 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements regarding our short-term objectives and opportunities, financial expectations for the full year and financial preparedness as of year end, as well as statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. 2 MULTIPLE LAYERS OF VALUE 1 approved product Validated Platform Technology 8 active programs (NIH, BARDA, BMS, Janssen) 2 focus areas Expertise in T-Cell Stimulation Infectious Disease & Oncology & Antibody Response 3 Phase 3 Products Broad Pipeline Multiple near-term milestones & Late-Stage Candidates $1.2B in US government contracts $900M in revenues over past 10 years Strong Revenue Base to $975M BMS deal - PROSTVAC Re-Invest in Clinical Pipeline $358M Janssen deals – Ebola and HPV 3 LIVE VIRUS VACCINE PLATFORM VALIDATED AND MODULAR
    [Show full text]
  • Re-Emergency of Ebola Epidemic in the Democratic Republic of Congo
    1 Re-emergency of Ebola Epidemic in the Democratic Republic of Congo: Synergizing the Preparedness and Response Measures with the Sustainable Development Goals Joseph Kimuli Balikuddembe Institute for Disaster Management and Reconstruction (IDMR), Sichuan University and The Hong Kong Polytechnic University, Chengdu, Sichuan Province, China 2 Abstract Ebola outbreaks which have re-emerged in the Democratic Republic Congo (DRC) have continued to galvanize the regional and global attention. The outbreaks are likely to transcend borders and threaten the global health crisis, especially by ensuring the “healthy lives and to promote the well-being for all at all ages” which is grounded in the sustainable development goals (SDGs). In this regard, the present paper attempts to discuss the synergies between the SDGs and Ebola preparedness and response measures - with a specific outlook on the in SDG.3 and the recent Ebola outbreak in the DRC. This aims at showing how the five (5) targets in SDG.3 can be prioritized and integrated in the Ebola preparedness and response measures taken against the battle of any sporadic health disasters and emergencies similar to Ebola. The targets include: end epidemics of infectious diseases; achieve universal health coverage; support research and the development of vaccines and medicines; increase health financing and recruitment, development, training and retention of the health workforce; and strengthen the capacity for early warnings, risk reduction and management. The paper ends by calling for an approach which elucidated an interaction between the environmental factors and countermeasures of responding to re-emergency and transmission of this deadly disease in the DRC and elsewhere.
    [Show full text]
  • Bavarian Nordic Secures Second Part of Smallpox Vaccine Order from the U.S
    Company Announcement Bavarian Nordic Secures Second Part of Smallpox Vaccine Order from the U.S. Government COPENHAGEN, Denmark, December 16, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised an option covering the majority of the second year of performance under the USD $200 million order for JYNNEOS® (Smallpox and Monkeypox Vaccine, Live, Non-replicating) awarded in April 2020. The first USD $106 million covered both manufacturing of bulk vaccine and supply of liquid-frozen JYNNEOS doses and was secured upon contract award last April. With the current option, BARDA is committing to an additional USD $83 million for the procurement of more bulk smallpox vaccine, which will be manufactured and invoiced in 2021. The last option of the order, amounting to USD 12 million, is for the supply of additional liquid-frozen JYNNEOS doses that will be manufactured in the Company’s new fill and finish facility and is expected to be awarded and invoiced during 2021. These options extend the contract awarded to Bavarian Nordic in 2017 and will secure the long-term manufacturing and supply of JYNNEOS for the U.S. government, including adding a freeze-dried version of the vaccine in the coming years. Paul Chaplin, President and CEO of Bavarian Nordic said: “We are pleased to continue our strong public-private partnership with the U.S. government on the development and supply of biological countermeasures.
    [Show full text]
  • 191021-Conference-Call.Pdf
    Bavarian Nordic in transformative acquisition of two commercial vaccines from GlaxoSmithKline Forward-looking statements This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements regarding our short-term objectives and opportunities, financial expectations for the full year and financial preparedness as of year end, as well as statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward- looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. 2 Transformative transaction that will establish a leading infectious disease franchise and accelerate Bavarian Nordic’s pathway to profitability Accelerates our vision by 3 years to become a leading and profitable vaccine company Exploits significant manufacturing synergies between highly complementary technologies and builds on our expertise Strong cash flow generation allows us to continue progressing our promising innovative pipeline Executing on our strategy to create a strong
    [Show full text]
  • Ebola Vaccine Regimen from Johnson & Johnson and Bavarian Nordic
    Press Release Ebola Vaccine Regimen from Johnson & Johnson and Bavarian Nordic Supports World Health Organization in Efforts to Prevent Spread of Ebola in West Africa COPENHAGEN, Denmark, May 17, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that its partner Johnson & Johnson is supporting efforts by the World Health Organization (WHO) to prevent further spread of Ebola in West Africa through the donation of up to 200,000 courses of the Johnson & Johnson Ebola vaccine regimen. The Johnson & Johnson Ebola vaccine regimen includes Mvabea®, which was developed and manufactured by Bavarian Nordic. The vaccine regimens are being made available through an early access clinical program directed by the WHO and national governments, and the first doses were administered last week in Sierra Leone. Additionally, the Johnson & Johnson Ebola vaccine regimen has received Prequalification from the WHO, which along with the July 2020 approval from the European Commission, will help accelerate its registration in countries where Ebola is a persistent public health threat and facilitate broader access to people at risk of exposure to this virus. The regimen is designed to be used proactively induce immunity against Ebola virus disease in adults and children. Paul Chaplin, President and CEO of Bavarian Nordic said: “We are proud to be part of the strong commitment from Johnson & Johnson in the fight against Ebola, and we continue to support these efforts through manufacturing of vaccines to meet the increasing demand. Vaccines remain
    [Show full text]